Exact Sciences Corporation (BMV:EXAS)

Market Cap	336.93B +60.8%
Revenue (ttm)	56.53B +14.5%
Net Income	-18.10B
EPS	-96.55
Shares Out	n/a
PE Ratio	n/a
Forward PE	121.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	141
Average Volume	442
Open	890.12
Previous Close	1,050.00
Day's Range	890.12 - 890.12
52-Week Range	890.12 - 1,050.00
Beta	n/a
RSI	39.66
Earnings Date	Feb 17, 2026

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Ri...

• Industry: Commercial Physical and Biological Research
• Founded: 1995
• Employees: 7,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: EXAS

Financial Performance

In 2024, Exact Sciences's revenue was $2.76 billion, an increase of 10.37% compared to the previous year's $2.50 billion. Losses were -$1.03 billion, 404.0% more than in 2023.

Financial numbers in USD